FDA Backs Off Joint Study On Kratom And Psychedelics Amidst Public Criticism
The Food and Drug Administration (FDA) has unexpectedly withdrawn its request for White House permission to conduct a study on the risks associated with kratom and psychedelics. As Marijuana Moment reported, this move comes in response to growing public criticism, particularly from advocates who have accused the agency of displaying a consistent bias against harm reduction strategies.
Kratom Use in the U.S.
Kratom is a tropical tree (Mitragyna Speciosa) native to Southeast Asia with opiate-like properties. Although the FDA has not approved any use of kratom, it is often used to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression as well as opioid use disorder and withdrawal. An estimated 1.7 million Americans aged 12 and older used kratom in 2021, according to the National Survey on Drugs Use and Health.
Introduction Of The Federal Kratom Consumer Protection Act
In June 2023, Congress introduced H.R.5905, the Federal Kratom Consumer Protection Act. This bill required the FDA to hold a hearing and establish a task force on the health and safety of kratom products. It also prohibited the FDA from regulating kratom products in a more …